| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Michael Amoroso
Also a director
President, Chief Executive Officer and Director
|
48 |
Since 2021
5 years
|
Not stated | $2,189,467 | |
|
Alex Kelly
Chief Financial Officer
|
59 |
Since 2021
5 years
|
Not stated | $1,134,116 | |
|
Naresh Haresh Tanna
Chief Financial Officer
Title from the Form 3 dated Aug 1, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
John Alexander Kelly
Chief Financial Officer
Title from the Form 4 dated Jun 1, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Dario Scimeca
General Counsel and Secretary
|
51 |
Since 2019
7 years
|
Not stated | $911,641 | |
|
Jeff Smith
Chief Research Officer
|
53 |
Since 2022
4 years
|
2006 | Not reported | |
|
Cassandra Louise Gorsuch
Chief Scientific Officer
Title from the Form 3 dated Aug 1, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Mei Zhang Lu Burris
Chielf Accounting Officer
Title from the Form 3 dated Aug 1, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Investors’ rights agreement providing rights to several holders, with certain registration rights surviving until the fifth anniversary of the IPO.
Company agreed to indemnify directors and executive officers against certain liabilities, costs and expenses and purchased directors’ and officers’ liability insurance.
Employment agreements with each executive officer, including named executive officers.
Stock options and restricted stock units granted to executive officers.
April 2006 license agreement under which Duke granted the company an exclusive license under certain patents related to meganucleases.
Dr. Smith, as an inventor of licensed patents, is entitled to a portion of income from those inventions under Duke’s inventors’ policy; he did not receive more than the threshold amount from Duke in the stated years.
Loading...
